Allison Kaeding

430 total citations
13 papers, 254 citations indexed

About

Allison Kaeding is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Allison Kaeding has authored 13 papers receiving a total of 254 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 4 papers in Immunology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Allison Kaeding's work include CAR-T cell therapy research (7 papers), Biosimilars and Bioanalytical Methods (3 papers) and Occupational and environmental lung diseases (3 papers). Allison Kaeding is often cited by papers focused on CAR-T cell therapy research (7 papers), Biosimilars and Bioanalytical Methods (3 papers) and Occupational and environmental lung diseases (3 papers). Allison Kaeding collaborates with scholars based in United States and Germany. Allison Kaeding's co-authors include Jessica H. Savage, Elizabeth C. Matsui, Robert A. Wood, Safiyyah Ziyad, Susan Bal, Jesús G. Berdeja, Larry D. Anderson, Luciano J. Costa, Michael R. Burgess and Tara Gregory and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Allergy and Clinical Immunology.

In The Last Decade

Allison Kaeding

13 papers receiving 242 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Allison Kaeding United States	6	115	76	64	58	45	13	254
Anke Fähnrich Germany	9	25 0.2×	34 0.4×	94 1.5×	22 0.4×	11 0.2×	28	256
Carah B. Santos United States	8	180 1.6×	31 0.4×	29 0.5×	23 0.4×	6 0.1×	11	369
Jin‐Lu Sun China	10	145 1.3×	34 0.4×	58 0.9×	3 0.1×	16 0.4×	22	307
Suresh Radhakrishnan India	9	48 0.4×	25 0.3×	56 0.9×	6 0.1×	33 0.7×	15	259
Detlef Bartel Germany	8	90 0.8×	8 0.1×	101 1.6×	14 0.2×	21 0.5×	15	317
Hitoshi Akiba Japan	9	101 0.9×	50 0.7×	44 0.7×	7 0.1×	9 0.2×	13	413
Andre Okanobo United States	8	60 0.5×	26 0.3×	59 0.9×	9 0.2×	12 0.3×	11	516
Hendrik Reuter Germany	9	41 0.4×	17 0.2×	110 1.7×	11 0.2×	4 0.1×	16	295
Pedro Mendes‐Bastos Portugal	10	158 1.4×	20 0.3×	16 0.3×	13 0.2×	34 0.8×	40	441
Renate Bauer Austria	10	61 0.5×	4 0.1×	124 1.9×	24 0.4×	16 0.4×	21	247

Countries citing papers authored by Allison Kaeding

Since Specialization

Citations

This map shows the geographic impact of Allison Kaeding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allison Kaeding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allison Kaeding more than expected).

Fields of papers citing papers by Allison Kaeding

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allison Kaeding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allison Kaeding. The network helps show where Allison Kaeding may publish in the future.

Co-authorship network of co-authors of Allison Kaeding

This figure shows the co-authorship network connecting the top 25 collaborators of Allison Kaeding. A scholar is included among the top collaborators of Allison Kaeding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allison Kaeding. Allison Kaeding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Bal, Susan, Myo Htut, Jesús G. Berdeja, et al.. (2024). BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1-3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results. Blood. 144(Supplement 1). 2069–2069. 2 indexed citations

Bal, Susan, Larry D. Anderson, Omar Nadeem, et al.. (2024). Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM). Blood. 144(Supplement 1). 922–922. 8 indexed citations

Bal, Susan, Myo Htut, Omar Nadeem, et al.. (2023). BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study. Blood. 142(Supplement 1). 219–219. 32 indexed citations

Bal, Susan, Jesús G. Berdeja, Myo Htut, et al.. (2023). S193: BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1 STUDY. HemaSphere. 7(S3). e9863287–e9863287. 13 indexed citations

Bal, Susan, Mehmet H. Kocoglu, Omar Nadeem, et al.. (2022). Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study. Blood. 140(Supplement 1). 883–885. 32 indexed citations

Gopalakrishnapillai, Anilkumar, Colin Correnti, Ashok D. Bandaranayake, et al.. (2021). Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies. Cancers. 13(23). 5964–5964. 6 indexed citations

Gopalakrishnapillai, Anilkumar, Allison Kaeding, Christoph A. Schatz, et al.. (2019). In Vivo Evaluation of Mesothelin As a Therapeutic Target in Pediatric Acute Myeloid Leukemia. Blood. 134(Supplement_1). 1370–1370. 4 indexed citations

Gopalakrishnapillai, Anilkumar, Colin Correnti, Anne Kisielewski, et al.. (2019). Mesothelin Targeting Bites for Pediatric AML: In Vivo Efficacy and Specificity. Blood. 134(Supplement_1). 3925–3925. 1 indexed citations

Kaeding, Allison, Katherine Tarlock, E. Anders Kolb, & Soheil Meshinchi. (2018). Immunotherapeutic Targeting of Mesothelin in Acute Myeloid Leukemia in Vitro with Anetumab Ravtansine and a Novel Antibody-Drug Conjugate. Blood. 132(Supplement 1). 1448–1448. 4 indexed citations

10.

Kaeding, Allison, Katherine Tarlock, Sonali P. Barwe, et al.. (2017). Mesothelin Is a Novel Disease Marker and Potential Therapeutic Target in Pediatric Acute Myeloid Leukemia. Blood. 130. 2641–2641. 1 indexed citations

11.

Sun, Di, Allison Kaeding, Daniel Magoon, et al.. (2012). Safety and biological activity of the FLT3 inhibitor lestaurtinib in infant MLL-rearranged (MLL-r) ALL: Children's Oncology Group protocol AALL0631.. Journal of Clinical Oncology. 30(15_suppl). 9548–9548. 3 indexed citations

12.

Savage, Jessica H., Allison Kaeding, Elizabeth C. Matsui, & Robert A. Wood. (2010). The natural history of soy allergy. Journal of Allergy and Clinical Immunology. 125(3). 683–686. 147 indexed citations

13.

Kaeding, Allison, et al.. (1975). [What will become of untreated hemangiomas?].. PubMed. 161(12). 977–88. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact